BioSpace News Archive

SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) (“SELLAS” or the “Company”) today announced that Angelos Stergiou, MD, ScD h.c., President and Chief Executive Officer of SELLAS, and members of the SELLAS management team will participate in a panel presentation and one-on-one investor meetings at the Cantor Fitzgerald Global Healthcare Conference, taking place in New York, NY, from September 26-28, 2023.

Kintara Therapeutics, Inc. (NASDAQ: KTRA) (“Kintara” or the “Company”), a biopharmaceutical company focused on the development of new solid tumor cancer therapies, today announced financial results for its fiscal year ended June 30, 2023 and provided a corporate update.

BIOLASE, Inc. announced the closing of its previously announced underwritten public offering of 75,000 units, with each Unit consisting of one share of BIOLASE’s Series J Convertible Redeemable Preferred Stock, par value $0.001 per share, with a liquidation preference of $100.00 per share, and one warrant to purchase one-half of one share of Series J Convertible Preferred Stock.

Johnson & Johnson will host a conference call for investors at 8:30 a.m. on Tuesday, October 17th to review third-quarter results. Joseph J. Wolk, Executive Vice President and Chief Financial Officer and Jessica Moore, Vice President, Investor Relations will host the call.

Astellas Venture Management LLC (President: William Watt, Ph.D., “AVM”), a wholly owned venture capital subsidiary of Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, “Astellas”), and MBC BioLabs, a premier launchpad for early-stage life-science companies, today announced their collaboration on the Astellas Future Innovator Prize.